New Zealand - English - Medsafe (Medicines Safety Authority)

carsl consulting - aripiprazole 15mg - tablet - 15 mg - active: aripiprazole 15mg excipient: hyprolose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. aripiprazole monotherapy is indicated for acute and maintenance treatment of manic and mixed episodes with bipolar i disorder with or without psychotic features. aripiprazole is indicated as an adjunctive therapy to either lithium or valporate for the acute treatment of manic and mixed episodes associated with bipolar i disorder with or without psychotic features.

New Zealand - English - Medsafe (Medicines Safety Authority)

carsl consulting - aripiprazole 20mg - tablet - 20 mg - active: aripiprazole 20mg excipient: hyprolose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. aripiprazole monotherapy is indicated for acute and maintenance treatment of manic and mixed episodes with bipolar i disorder with or without psychotic features. aripiprazole is indicated as an adjunctive therapy to either lithium or valporate for the acute treatment of manic and mixed episodes associated with bipolar i disorder with or without psychotic features.

New Zealand - English - Medsafe (Medicines Safety Authority)

carsl consulting - aripiprazole 30mg - tablet - 30 mg - active: aripiprazole 30mg excipient: hyprolose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. aripiprazole monotherapy is indicated for acute and maintenance treatment of manic and mixed episodes with bipolar i disorder with or without psychotic features. aripiprazole is indicated as an adjunctive therapy to either lithium or valporate for the acute treatment of manic and mixed episodes associated with bipolar i disorder with or without psychotic features.

New Zealand - English - Medsafe (Medicines Safety Authority)

carsl consulting - aripiprazole 5mg - tablet - 5 mg - active: aripiprazole 5mg excipient: hyprolose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. aripiprazole monotherapy is indicated for acute and maintenance treatment of manic and mixed episodes with bipolar i disorder with or without psychotic features. aripiprazole is indicated as an adjunctive therapy to either lithium or valporate for the acute treatment of manic and mixed episodes associated with bipolar i disorder with or without psychotic features.

New Zealand - English - Medsafe (Medicines Safety Authority)

carsl consulting - drospirenone 3mg; ethinylestradiol 0.03mg - film coated tablet - 3 mg/0.03 mg - active: drospirenone 3mg ethinylestradiol 0.03mg excipient: lactose monohydrate magnesium stearate maize starch opadry yellow 03f82726 pregelatinised maize starch purified water lactose monohydrate magnesium stearate maize starch opadry white 03b28796 pregelatinised maize starch purified water - oral contraception

New Zealand - English - Medsafe (Medicines Safety Authority)

carsl consulting - oxymetazoline hydrochloride 0.5 mg/ml - nasal spray solution - 0.5 mg/ml - active: oxymetazoline hydrochloride 0.5 mg/ml excipient: acesulfame potassium aloe vera benzalkonium chloride benzyl alcohol carvone cineole citric acid disodium edetate levomenthol polysorbate 80 purified water sodium citrate dihydrate sorbitol - temporary relief of nasal congestion due to colds, allergies and sinusitis.

New Zealand - English - Medsafe (Medicines Safety Authority)

carsl consulting - oxymetazoline hydrochloride 0.5 mg/ml - nasal spray solution - 0.5 mg/ml - active: oxymetazoline hydrochloride 0.5 mg/ml excipient: benzalkonium chloride benzyl alcohol camphor cineole citric acid disodium edetate levomenthol polysorbate 80 purified water sodium citrate dihydrate sorbitol - temporary relief of nasal congestion due to colds, allergies and sinusitis

New Zealand - English - Medsafe (Medicines Safety Authority)

carsl consulting - atorvastatin calcium trihydrate 10.845mg equivalent to atorvastatin 10 mg;   - coated tablet - 10 mg - active: atorvastatin calcium trihydrate 10.845mg equivalent to atorvastatin 10 mg   excipient: calcium carbonate candelilla wax croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7040 polysorbate 80 purified water   simethicone emulsion usp - dp-atorvastatin is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia where the primary abnormality is elevated cholesterol when response to diet and other non-pharmacological measures is inadequate. dp-atorvastatin is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia. dp-atorvastatin is indicated to increase plasma hdl-c and decrease the ldl-c/hdl-c and total cholesterol/hdl-c ratios. dp-atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum triglyceride levels (hypertriglyceridaemia).

New Zealand - English - Medsafe (Medicines Safety Authority)

carsl consulting - atorvastatin calcium trihydrate 21.69mg equivalent to atorvastatin 20 mg;   - coated tablet - 20 mg - active: atorvastatin calcium trihydrate 21.69mg equivalent to atorvastatin 20 mg   excipient: calcium carbonate candelilla wax croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7040 polysorbate 80 purified water   simethicone emulsion usp - dp-atorvastatin is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia where the primary abnormality is elevated cholesterol when response to diet and other non-pharmacological measures is inadequate. dp-atorvastatin is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia. dp-atorvastatin is indicated to increase plasma hdl-c and decrease the ldl-c/hdl-c and total cholesterol/hdl-c ratios. dp-atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum triglyceride levels (hypertriglyceridaemia).

New Zealand - English - Medsafe (Medicines Safety Authority)

carsl consulting - atorvastatin calcium trihydrate 43.38mg equivalent to atorvastatin 40 mg;   - coated tablet - 40 mg - active: atorvastatin calcium trihydrate 43.38mg equivalent to atorvastatin 40 mg   excipient: calcium carbonate candelilla wax croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7040 polysorbate 80 purified water   simethicone emulsion usp - dp-atorvastatin is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia where the primary abnormality is elevated cholesterol when response to diet and other non-pharmacological measures is inadequate. dp-atorvastatin is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia. dp-atorvastatin is indicated to increase plasma hdl-c and decrease the ldl-c/hdl-c and total cholesterol/hdl-c ratios. dp-atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum triglyceride levels (hypertriglyceridaemia).